Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellectar BiosciencesCLRB -3.29%25 3-Year EPS without NRI Growth Rate is 61.40% as of Jun. 2026, which is 14% above its 10-year median of 53.70. GuruFocus rates CLRB with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Cellectar Biosciences ranks better than 90.26% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 61.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 43.10% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 49.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Cellectar Biosciences was 61.40% per year. The lowest was 25.40% per year. And the median was 53.70% per year.
Cellectar Biosciences (NAS:CLRB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Cellectar Biosciences 3-Year EPS without NRI Growth Rate Related Terms
CLRB vs ENLV, TVRD, PVCT: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Cellectar Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectar Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Cellectar Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 61.40% mean?
Cellectar Biosciences (CLRB) has a 3-Year EPS without NRI Growth Rate of 61.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cellectar Biosciences and its competitors. This is 14% above median its historical median of 53.70. Over the past decade, Cellectar Biosciences' 3-Year EPS without NRI Growth Rate has ranged from 25.40 to 61.40. According to the industry distribution chart, Cellectar Biosciences ranks #113 out of 1160 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Cellectar Biosciences' 3-Year EPS without NRI Growth Rate too high?
Cellectar Biosciences' current 3-Year EPS without NRI Growth Rate of 61.40% is 14% above median its 10-year median of 53.70. Over the past 10 years, this metric has ranged from a low of 25.40 to a high of 61.40. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Cellectar Biosciences' value of 61.40% is 282.6% above this industry median. Based on the distribution chart, Cellectar Biosciences ranks #113 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cellectar Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' 3-Year EPS without NRI Growth Rate compare to ENLV and TVRD?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #113 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Cellectar Biosciences in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Cellectar Biosciences' value of 61.40% is 282.6% above this benchmark. Historically, Cellectar Biosciences' own 3-Year EPS without NRI Growth Rate has ranged from 25.40 to 61.40 over the past decade. While the company's 10-year median is 53.70 vs. the industry median of 16.05, Cellectar Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellectar Biosciences's current 3-Year EPS without NRI Growth Rate of 61.40% is 282.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cellectar Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellectar Biosciences's current 3-Year EPS without NRI Growth Rate is 61.40%, which is 14% above median its own 10-year median of 53.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current 3-Year EPS without NRI Growth Rate of 61.40%. The current 3-Year EPS without NRI Growth Rate is 61.40%, which is 14% above median its 10-year median of 53.70 and 282.6% above the Biotechnology industry median of 16.05. Cellectar Biosciences' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current 3-Year EPS without NRI Growth Rate is 61.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
25GF Score
Get the complete analysis for CLRB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLRB has been successfully added to your 
